Yamada N, Kato M, ten Dijke P, Yamashita H, Sampath T K, Heldin C H, Miyazono K, Funa K
Ludwig Institute for Cancer Research, Uppsala, Sweden.
Br J Cancer. 1996 Mar;73(5):624-9. doi: 10.1038/bjc.1996.108.
The distribution of bone morphogenetic protein (BMP) type I receptors and the activin type I receptor (ActR-I) was investigated in 16 cases of human glioma and five cases of non-tumourous gliosis tissue by immunohistochemical technique. Both BMP type IA (BMPR-IA) and the type IB (BMPR-IB) receptors were detected in human glioma cells. A significant increase in BMPR-IB in tumour cells was observed in malignant glioma compared with both low-grade astrocytomas (n=16, P<0.005) and gliosis (n=13, P<0.001). However, enhancement of BMPR-IA staining was moderate and ActR-I staining was only weakly expressed in the malignant glioma tumours. Osteogenic protein (OP)-1/BMP-7, which is known to bind BMPR-IA, BMPR-IB and ActR-I, was expressed in nervous tissue and was also detected in anaplastic areas of malignant glioma. In contrast to the tissue materials, BMPR-IA was expressed to a stronger degree than BMPR-IB in human glioma cell lines; the growth of these cells was suppressed by OP-1. These results suggest the presence of BMP receptors and a functional role for BMPs in malignant glioma.
采用免疫组织化学技术，对16例人脑胶质瘤组织和5例非肿瘤性胶质增生组织中骨形态发生蛋白（BMP）I型受体及激活素I型受体（ActR-I）的分布进行了研究。在人脑胶质瘤细胞中检测到了BMP IA型（BMPR-IA）和IB型（BMPR-IB）受体。与低级别星形细胞瘤（n = 16，P < 0.005）和胶质增生（n = 13，P < 0.001）相比，在恶性胶质瘤的肿瘤细胞中观察到BMPR-IB显著增加。然而，在恶性胶质瘤肿瘤中，BMPR-IA染色增强程度中等，ActR-I染色仅呈弱表达。已知可结合BMPR-IA、BMPR-IB和ActR-I的成骨蛋白（OP）-1/BMP-7在神经组织中表达，在恶性胶质瘤的间变区域也可检测到。与组织材料不同，在人胶质瘤细胞系中，BMPR-IA的表达程度强于BMPR-IB；OP-1可抑制这些细胞的生长。这些结果提示，BMP受体存在于恶性胶质瘤中，且BMP在其中发挥功能作用。
